Holbrook E Kohrt
Overview
Explore the profile of Holbrook E Kohrt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
4047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khodadoust M, Rook A, Porcu P, Foss F, Moskowitz A, Shustov A, et al.
J Clin Oncol
. 2019 Sep;
38(1):20-28.
PMID: 31532724
Purpose: To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS). Patients And Methods: CITN-10 is a single-arm, multicenter phase...
2.
Kohrt H, Colevas A, Houot R, Weiskopf K, Goldstein M, Lund P, et al.
J Clin Invest
. 2019 Jun;
129(6):2595.
PMID: 31157621
No abstract available.
3.
Kohrt H, Houot R, Weiskopf K, Goldstein M, Scheeren F, Czerwinski D, et al.
J Clin Invest
. 2019 Jun;
129(6):2595.
PMID: 31157620
No abstract available.
4.
Khodadoust M, Olsson N, Wagar L, Haabeth O, Chen B, Swaminathan K, et al.
Nature
. 2017 Mar;
543(7647):723-727.
PMID: 28329770
Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. However, the personalized identification and validation of neoantigens remains a major challenge. Here we discover neoantigens in human...
5.
Myklebust J, Brody J, Kohrt H, Kolstad A, Czerwinski D, Walchli S, et al.
Blood
. 2016 Dec;
129(6):759-770.
PMID: 28011673
Kinases downstream of B-cell antigen receptor (BCR) represent attractive targets for therapy in non-Hodgkin lymphoma (NHL). As clinical responses vary, improved knowledge regarding activation and regulation of BCR signaling in...
6.
Souza-Fonseca-Guimaraes F, Blake S, Makkouk A, Chester C, Kohrt H, Smyth M
Oncoimmunology
. 2016 Sep;
5(7):e1192740.
PMID: 27622048
Studies of sequential anti-CD137/anti-CD20 therapy have previously shown that the efficacy of anti-CD20 was heavily reliant upon anti-CD137; however, the exact mechanism of the anti-B-cell lymphoma efficacy, and whether this...
7.
Liu J, Blake S, Harjunpaa H, Fairfax K, Yong M, Allen S, et al.
Cancer Res
. 2016 Aug;
76(18):5288-301.
PMID: 27503925
New combination immunotherapies are displaying both efficacy and immune-related adverse events (irAE) in humans. However, grade 3/4 irAEs occur in a high proportion, which can lead to discontinuation of treatment...
8.
Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt H
Immunotargets Ther
. 2016 Jul;
4:91-100.
PMID: 27471715
The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends on the capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxicity via a network of immune effector...
9.
Zhao X, Chester C, Rajasekaran N, He Z, Kohrt H
Mol Cancer Ther
. 2016 May;
15(5):767-73.
PMID: 27197256
The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low efficacy, toxicity, and treatment-resistant tumor subclones. Oncolytic viral therapy offers...
10.
Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Annamalai L, et al.
N Engl J Med
. 2016 Apr;
374(26):2542-52.
PMID: 27093365
Background: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses...